Unknown

Dataset Information

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.


ABSTRACT:

Objectives

To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia.

Methods

In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneous etanercept (50 mg) once weekly or identical placebo over a 24-week period. Tolerability and safety of this medication was recorded including secondary outcomes of cognition, global function, behavior, and systemic cytokine levels at baseline, 12 weeks, 24 weeks, and following a 4-week washout period. This trial is registered with EudraCT (2009-013400-31) and ClinicalTrials.gov (NCT01068353).

Results

Forty-one participants (mean age 72.4 years; 61% men) were randomized to e

SUBMITTER: Butchart J 

PROVIDER: S-EPMC4451045 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature